Every day, OncoDNA characterizes patients from all over the world… Most of our conclusions/reports are listing FDA or EMA approved treatments. But in some cases, the best or only treatment options left are compounds which are still under clinical development. So, some patients are in desperate need to get access to these clinical trial.
The other way around, they are more and more biopharmas involved in cancer treatment
development, which happily means more and more compounds being tested in clinical trials and more and more patients needed to complete these clinical trials. Also, as many of those compounds are targeting specific molecular events, eligible patients are more and more specific and difficult to find.
Our job ? Help both patients and biopharma with targeted recruitment fitting clinical trial design and needs. Our program leans on the fast growing number of patients and oncologists using OncoDEEP, OncoSTRAT&GO and OncoTRACE and on our OncoSHARE and OncoKDM databases.